

## 《子宮頸癌抗癌藥物治療指引》

### Neoadjuvant Chemotherapy of Cervical Cancer

#### POB

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	50	1	Q10D	3	4, 5
Vincristine	1 (Max 2 mg)	1	Q10D	3	
Bleomycin	25	1-3	Q10D	3	

#### Paclitaxel + Cisplatin

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	135	1	Q3W	6	6
Cisplatin	50	1	Q3W	6	

#### CCRT

#### Cisplatin

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	40*	1	QW	6	1, 2, 3

\*Maximal weekly dose: 70 mg

## Adjuvant Chemotherapy

### Paclitaxel + Cisplatin

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	135	1	Q3W	6	6, 7
Cisplatin	50	1	Q3W	6	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	175	1	Q3W	6	10
Cisplatin	50	1	Q3W	6	

### POB

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	50	1	Q10D	3	4, 5
Vincristine	1 (Max 2 mg)	1	Q10D	3	
Bleomycin	25	1-3	Q10D	3	

### Cisplatin + Topotecan

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	50	1	Q3W	6	8
Topotecan	0.75	1-3	Q3W	6	

**Cisplatin + Gemcitabine**

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	30	1, 8	Q4W		9
Gemcitabine	800	1, 8	Q4W		

**參考文獻**

1. Gaffney DK, Erickson-Wittmann BA, Jhingran A, et al. ACR Appropriateness Criteria(R) on Advanced Cervical Cancer Expert Panel on Radiation Oncology-Gynecology. *Int J Radiat Oncol Biol Phys* 2011;81:609-614.
2. Monk BJ, Tewari KS, Koh W-J. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. *J Clin Oncol* 2007;25:2952-2965.
3. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. *N Engl J Med* 1999;340:1154-1161.
4. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. *N Engl J Med* 1999;340:1137-1143.
5. Peters WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. *J Clin Oncol* 2000;18:1606-1613.
6. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. *J Clin Oncol* 1999;17:1339-1348.
7. Sardi LE, Giaroli A, Sananes C, et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. *Gynecol Oncol* 1997;67:61-9.
8. Chang TC, Lai CH, Hong JH, Hsueh S, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer.
9. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB,

- recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol.*2009;27(28):4649–4655.
10. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. *J Clin Oncol.*2004;22(15):3113–3119.
  11. Long HJ 3rd, Bundy BN, Grendys EC Jr, et al; Gynecologic Oncology Group Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. *J Clin Oncol.* 2005; 23:4626–4633.
  12. Brewer CA, Blessing JA, Nagourney RA, et al. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. *Gynecol Oncol.* 2006;100:385–388.
  13. The ICON and AGO Collaborators, Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial, *Lancet.* 2003;361:2099-106.

## Chemotherapy Regimens for Recurrent or Metastatic Cervical Cancer

### First-line therapy

#### For PD-L1 positive

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Pembrolizumab*	200 mg	1	Q3W		9
Bevacizumab	15 mg/kg	1	Q3W	6	
Paclitaxel	135 or 175	1	Q3W	6	
Cisplatin	50	1	Q3W	6	

\*For PD-L1 positive

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Pembrolizumab*	200 mg	1	Q3W		9
Bevacizumab	15 mg/kg	1	Q3W	6	
Paclitaxel	135 or 175	1	Q3W	6	
Carboplatin	AUC 5	1	Q3W	6	

\*For PD-L1 positive

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	1	Q3W	6	1-3
Paclitaxel	135 or 175	1	Q3W	6	
Cisplatin	50	1	Q3W	6	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	1	Q3W	6	2, 3
Carboplatin	AUC 6	1	Q3W	6	
Paclitaxel	135 or 175	1	Q3W	6	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	1	Q3W		1
Paclitaxel	175	1	Q3W		
Topotecan	0.75	1-3	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	175	1	Q3W	Max 6	4, 5
Carboplatin	AUC 5	1	Q3W	Max 6	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	50	1	Q3W	Max 6	6
Topotecan	0.75	1	Q3W	Max 6	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	50	1	Q3W	6	3

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	400	1	Q4W		7

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	250	1	Q3W		8

### Second-line therapy

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	1	Q2W		10

★三院有個別版本

### 參考文獻

1. Tewari KS1, Sill MW, Long HJ 3rd, et al. Improved Survival with Bevacizumab in Advanced Cervical Cancer. N Engl J Med. 2014 Feb 20; 370(8):734-43
2. Monk BJ, Sill MW, McMeekin DS, et al. Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2009;27:4649-4655.
3. Moore DH, Blessing JA, McQuellon RP, et al. Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. J Clin Oncol 2004;22:3113-3119.
4. Moore KN, Herzog TJ, Lewin S, et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 2007;105:299-303.
5. Kitagawa R, Katsumata N, Shibata T, et al. A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505)[abstract]. J Clin Oncol 2012;30(Suppl 15):Abstract 5006.
6. Long HJ, 3rd, Bundy BN, Grendys EC, Jr., et al. Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study. J Clin Oncol 2005;23:4626-4633.

7. Weiss GR, Green S, Hannigan EV, et al. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: A Southwest Oncology Group Study. *Gynecol Oncol* 1990;39:332-336.
8. Kudelka AP, Winn R, Edwards CL, et al. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. *Anticancer Drugs* 1997;8:657-661.
9. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. *N Engl J Med*. 2021.
10. Naumann RW, Hollebecque A, Meyer T, et al. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. *J Clin Oncol*. 2019;37:2825-2834.



## 《子宮內膜癌抗癌藥物治療指引》

### Systemic Therapy for Recurrent, Metastatic or High-Risk Disease

#### Hormone Therapy

Megestrol/tamoxifen(alternating)

Progestational agents

Aromatase inhibitors

Tamoxifen

#### Chemotherapy Regimens

Multi-agent chemotherapy regimens preferred, if tolerated

##### Paclitaxel + Carboplatin

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W	7	1
Paclitaxel	175	1	Q3W	7	

##### Doxorubicin + Cisplatin + Paclitaxel

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Doxorubicin	45	1	Q3W	6	2, 8
Cisplatin	50	1	Q3W	6	
Paclitaxel	160	2	Q3W	6	

### Paclitaxel + Cisplatin

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	135 or 175	1	Q3W	6	14
Cisplatin	50	1	Q3W	6	

### Ifosfamide + Paclitaxel (for carcinosarcoma)

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	135	1	Q3W	Max 8	3
Ifosfamide	1600 (1200 with RT)	1-3	Q3W	Max 8	

### Ifosfamide + Cisplatin (for carcinosarcoma)

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Ifosfamide	1500	1-5	Q3W	3	4
Cisplatin	20	1-5	Q3W	3	

### Carboplatin + Paclitaxel + Bevacizumab

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	1	Q3W	16	16
Carboplatin	AUC 5	1	Q3W	6	
Paclitaxel	175	1	Q3W	6	

**Carboplatin + Paclitaxel + Trastuzumab**

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Trastuzumab	8 → 6 mg/kg	1	Q3W		17
Carboplatin	AUC 5	1	Q3W		
Paclitaxel	175	1	Q3W		

**Carboplatin + Docetaxel**

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W		18
Docetaxel	75	1	Q3W		

**Lenvatinib + Pembrolizumab**

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Lenvatinib	20 mg QD PO				7
Pembrolizumab	200 mg		Q3W		

**Single Agents**

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	1	Q3W		5

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	50-100	1	Q3W		12, 13

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 4-6	1	Q3W		12

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Topotecan	0.5-1.5	1-5	Q3W		9, 10

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Topotecan	1.5	1-5	Q3W		10

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Doxorubicin	50-60	1	Q3W		12

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Lipo-Doxorubicin	50	1	Q4W		11

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	250	1	Q3W		12

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Temsirolimus	25 mg	1	QW		19

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Pembrolizumab*	200 mg	1	Q3W		20

\*for MSI-H/ dMMR tumors

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Nivolumab	3 mg/kg	1	Q2W		22
followed by Nivolumab	480 mg	1	Q4W		

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Avelumab*	1500 mg	1	Q4W		24

\*for MSI-H/ dMMR tumors

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cabozantinib	60 mg	1	QD		25

### Ifosfamide (for carcinosarcoma)

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Ifosfamide	1200-2000*	1	Q3W	8	21

\*The starting dose was 1.2 g/m<sup>2</sup> for patients who had received prior RT.

## Adjuvant therapy

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	175	1	Q3W	7	1
Carboplatin	AUC 6	1	Q3W	7	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Doxorubicin	50	1	Q3W		6
Cisplatin	50	1	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	135 or 175	1	Q3W	6	14
Carboplatin	AUC 5-6	1	Q3W	6	

## Adjuvant Chemoradiation (Uterine-Confined Disease)

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Doxorubicin	50	1	Q3W		6
Cisplatin	50	1	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5-6	1	Q3W	6	15
Paclitaxel	175	1	Q3W	6	

\*三院有個別版本

## 參考文獻

1. Miller D, Filiaci V, Fleming G, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study [abstract]. *Gynecol Oncol* 2012;125:771.
2. Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. *Gynecol Oncol* 2009;112:543-552.
3. Homesley HD, Filiaci V, Markman M, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. *J Clin Oncol* 2007;25:526-531.
4. Sutton G, Kauderer J, Carson LF, et al. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. *Gynecol Oncol* 2005;96:630-634.
5. Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. *J Clin Oncol* 2011;29:2259-2265.
6. Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer—results from two randomised studies. *Eur J Cancer* 2010;46:2422-2431.
7. Makker V, Rasco D, Nicholas NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. *Lancet Oncol* 2019;20:711-718.
8. Miller D, Filiaci V, Fleming G, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study [abstract]. *Gynecologic Oncology* 2012;125:771.
9. Miller DS, Blessing JA, Lentz SS, Waggoner SE. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study. *Gynecol Oncol* 2002;87:247-251.
10. Wadler S, Levy DE, Lincoln ST, et al. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. *J Clin Oncol* 2003;21:2110-2114.
11. Muggia FM, Blessing JA, Sorosky J, Reid GC. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. *J Clin Oncol* 2002;20:2360-2364.

12. Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group Study. *J Clin Oncol* 2011;29:2259-2265.
13. Moxley KM, McMeekin DS. Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents. *Oncologist* 2010;15:1026-1033.
14. Thigpen JT, Blessing JA, Lagasse LD. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol.* 1989;33:68-70.
15. Connelly E, Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. *Gynecol Oncol.* 1996 Aug;62(2):166-8.
16. Gil Shechter-Maor; Ilan Bruchim; Zipi Ben-Harim, et al. Combined Chemotherapy Regimen of Carboplatin and Paclitaxel as Adjuvant Treatment for Papillary Serous and Clear Cell Endometrial Cancer. *International Journal of Gynecological Cancer* 2009;19(4):662-664.
17. Gil Shechter-Maor; Ilan Bruchim; Zipi Ben-Harim, et al. Combined Chemotherapy Regimen of Carboplatin and Paclitaxel as Adjuvant Treatment for Papillary Serous and Clear Cell Endometrial Cancer. *International Journal of Gynecological Cancer* 2009;19(4):662-664.
18. Rose PG, Ali S, et al. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma. *International Journal of Gynecological Cancer* 2017;27(3):452-458.
19. Amanda N. Fader, Dana M. Roque, et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. *J Clin Oncol.* 2018;27:JCO2017765966.
20. Geller MA, Ivy JJ, Ghebre R, et al. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. *Gynecol Oncol.* 2011;121(1):112-117.
21. Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. *J Clin Oncol.* 2011;29(24):3278-3285.



22. Azad NS, Gray RJ, Overman MJ, Schoenfeld JD, et al. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. *J Clin Oncol*. 2020 Jan 20;38(3):214-222. doi: 10.1200/JCO.19.00818. Epub 2019 Nov 25. PMID: 31765263; PMCID: PMC6968795.
23. Homesley HD, Filiaci V, Markman M, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. *J Clin Oncol*. 2007;25(5):526-531
24. Antill YC, Kok PS, Robledo K, et al. . Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601). *J Clin Oncol* 2019;37:5501–01. 10.1200/JCO.2019.37.15\_suppl.5501
25. Dhani NC, Hirte HW, Wang L, et al. Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). *Clin Cancer Res*. 2020 Jun 1;26(11):2477-2486. doi: 10.1158/1078-0432.CCR-19-2576. Epub 2020 Jan 28. PMID: 31992589; PMCID: PMC7269808.

## 《 卵巢癌抗癌藥物治療指引 》

### Chemotherapy as Primary or Adjuvant Therapy

#### IP/IV regimen

##### Paclitaxel + Cisplatin

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	135 IV	1	Q3W	6	1
Cisplatin	75 IV / 100 IP	2	Q3W	6	
Paclitaxel	60 IP	8	Q3W	6	

#### IV regimens

##### Paclitaxel + Carboplatin

藥品名	劑量 mg/m <sup>2</sup> *	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W	6	2
Paclitaxel	175	1	Q3W	6	

藥品名	劑量 mg/m <sup>2</sup> *	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W	6	3
Paclitaxel	80	1, 8, 15	Q3W	6	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 2	1	QW	18	8
Paclitaxel	60	1	QW	18	

**Docetaxel + Carboplatin**

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Docetaxel	75	1	Q3W	6	4
Carboplatin	AUC 6	1	Q3W	6	

**Carboplatin + Liposomal Doxorubicin**

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1	Q4W	6	11
Lipo-Doxorubicin	30	1	Q4W	6	

**Paclitaxel + Carboplatin + Bevacizumab**

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	7.5 mg/kg	1	Q3W	6-12	5
Carboplatin	AUC 5 or 6	1	Q3W	6	
Paclitaxel	175	1	Q3W	6	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	1	Q3W	22*	6
Carboplatin	AUC 6	1	Q3W	6	
Paclitaxel	175	1	Q3W	6	

\*Bevacizumab was initiated at cycle 2 to reduce the risk of wound-healing complications.

## PAC

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	50	1	Q3W	6	7
Doxorubicin	50	1	Q3W	6	
Cyclophosphamide	500	1	Q3W	6	

## PEC

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	60	1	Q3W		9
Epirubicin	60	1	Q3W		
Cyclophosphamide	750	1	Q3W		

## Post Primary treatment- Maintenance PARP inhibitor

\*newly diagnosed Stage II-IV or BCRA 1/2-mutated.

CR or PR is achieved after primary treatment with surgery and platinum-based 1st line.

### 1. Maintenance post primary chemotherapy +bevacizumab

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	1	Q3W	For 15 months	13
Olaparib	300 mg BID PO			For 1 year	

## 2. Maintenance post primary chemotherapy

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Niraparib	300 mg QD* PO	1	Q3W	For 36 months	14, 15

\*Or 200 mg QD for patients with a baseline body weight <77 kg, and/or PLT <150,000/mm<sup>3</sup>

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Olaparib	300 mg BID PO				16

## Malignant germ cell

### BEP

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bleomycin	20	1	Q3W	*	10
Cisplatin	20	1-5	Q3W		
Etoposide	75	1-5	Q3W		

\*3 cycles for good risk (category 2B), or 4 cycles for poor risk.

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Etoposide	120	1-3	Q4W	3	12
Carboplatin	AUC 5-6	1	Q4W	3	

## Neoadjuvant therapy

### Paclitaxel + Carboplatin

藥品名 *	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W	6	2
Paclitaxel	175	1	Q3W	6	

藥品名 *	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 2	1	QW	18	8
Paclitaxel	60	1	QW	18	

### BEP

藥品名 *	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bleomycin	20	1	Q3W	*	10
Cisplatin	20	1-5	Q3W		
Etoposide	75	1-5	Q3W		

\*3 cycles for good risk (category 2B), or 4 cycles for poor risk.

\*三院有個別版本

### 參考文獻

1. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.

2. John K. Chan, Mark F. Brady, et al. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. *N Engl J Med* 2016; 374:738-748.
3. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. *Lancet* 2009;374:1331-1338.
4. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. *J Natl Cancer Inst* 2004;96:1682-1691.
5. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med* 2011;365:2484-2496.
6. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med* 2011;365:2473-2483.
7. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. *Lancet* 2002;360:505-515.
8. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. *Lancet* 2009;374:1331-1338.
9. Massacesi C1, Bascioni R, et al. Cisplatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer. *J Exp Clin Cancer Res.* 2000 Mar;19(1):13-6.
10. Homesley HD, Bundy BN, Hurteau JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. *Gynecol Oncol.* 1999 Feb;72(2):131-7.
11. NCCN. [OV3 of 8] ovarian cancer: version 3, 2017.
12. Williams SD, Kauderer J, Burnett AF, Lentz SS, Aghajanian C, Armstrong DK. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. *Gynecol Oncol.* 2004;95(3):496-499.
13. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. *N Engl J Med* 2019;381:2416-2428.

14. Gonzalez-Martin A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381:2391- 2402.
15. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375:2154- 2164.
16. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379:2495-2505.



## Acceptable Recurrence Therapies

### First-line therapy

#### Platinum-Sensitive Disease

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	1, 8	Q3W	6 (Max 10)	1
Carboplatin	AUC 4	1	Q3W	6 (Max 10)	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	1	Q3W	6 (Max 10)	2
Gemcitabine	1000	1, 8	Q3W	6 (Max 10)	
Carboplatin	AUC 4	1	Q3W	6 (Max 10)	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	1	Q3W		18
Paclitaxel	175	1	Q3W		
Carboplatin	AUC 5	1	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	10 mg/kg	1, 15	Q4W	6	21
Lipo-Doxorubicin	30	1	Q4W	6	
Carboplatin	AUC 5	1	Q3W	6	
Followed by					
Bevacizumab	10 mg/kg	1	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1	Q4W	6	3
Lipo-Doxorubicin	30	1	Q4W	6	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1	Q3W	6	4
Paclitaxel	175	1	Q3W	6	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W	6	5
Paclitaxel	80	1, 8, 15	Q3W	6	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	75	1	Q3W	6	4

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Gemcitabine	750	1, 8	Q3W		6, 14
Cisplatin	30	1, 8	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 2	1	QW	18	8
Paclitaxel	60	1	QW	18	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	1	Q3W		22

MSI-H, or dMMR, or TMB-H

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Dostarlimab-gxly	500 mg	1	Q3W	4	23
followed by Dostarlimab-gxly	1000 mg	1	Q6W		

MSI-H

## Platinum-Resistant Disease

### Weekly Paclitaxel ± Pazopanib

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	80	1	QW		15
± Pazopanib	800 mg PO QD				

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	10 mg/kg	1	QW		15
Paclitaxel	80	1	QW		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	1, 8	Q3W		7

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	1, 8, 15	Q4W		8

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Lipo-Doxorubicin	40 or 50	1	Q4W		7, 8

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	10 mg/kg	1, 15	Q4W		9
Lipo-Doxorubicin	40	1	Q4W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Topotecan	1.25 or 1.5	1-5	Q3W		10, 11

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Topotecan	4	1, 8, 15	Q4W		11

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	1	Q3W		9
Topotecan	1.25	1-5	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	10 mg/kg	1, 15	Q4W		9
Topotecan	4	1, 8, 15	Q4W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	1	Q3W		12, 13

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	10 mg/kg	1	Q2W		20

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Olaparib	400 mg PO BID				16

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Docetaxel	100	1	Q3W		17

### Oral Etoposide

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Etoposide	50-60*	1-21	Q4W		19

\*reduced to 30 mg/m<sup>2</sup>/day for prior radiotherapy

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	1	Q3W		22

MSI-H, or dMMR, or TMB-H

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Dostarlimab-gxly	500 mg	1	Q3W	4	23
followed by Dostarlimab-gxly	1000 mg	1	Q6W		

MSI-H

\*三院有個別版本

## 參考文獻

1. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. *J Clin Oncol* 2006;24:4699-4707.
2. Aghajanian C, Blank SV, Goff BA, et al. A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. *J Clin Oncol* 2012;30:2039-2045.
3. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. *J Clin Oncol* 2010;28:3323-3329.
4. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. *Lancet* 2003;361:2099-2106.
5. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. *Lancet* 2009;374:1331-1338.

6. Rose PG. Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma. *Int J Gynecol Cancer* 2005;15:18-22.
7. Mutch DG, Orlando M, Goss T, et al. Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer. *J Clin Oncol* 2007;25:2811-2818.
8. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer. *J Clin Oncol* 2008;26:890-896.
9. Pujade-Lauraine E, Hilpert F, Wener B, et al. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. *J Clin Oncol* 2014;32(13):1302-1308.
10. Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. *Gynecol Oncol* 2004;95:1-8.
11. Shouli J, Stengel D, Harter P, et al. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. *J Clin Oncol* 2011;29:242-248.
12. Burger RA, Sill MW, Monk BJ, et al. Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study. *J Clin Oncol* 2007;25:5165-5171.
13. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer. *J Clin Oncol* 2007;25:5180-5186.
14. Rose PG, Mossbrugger K, Fusco N, Smrekar M, Eaton S, Rodriguez M. Gemcitabine reverses Cisplatin resistance: demonstration of activity in Platinum and multidrug-resistant ovarian and peritoneal carcinoma. *Gynecol Oncol* 2003; 88: 17-21.
15. Pignata S, Sandro D, Scambia G et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. *Lancet Oncol* 2015; 16:561-568.
16. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation. *J Clin Oncol* 2015;33:244-250.

17. Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2003;88(2):130-5.
18. Coleman RL, Brady MF, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* 2017 Jun;18(6):779-791.
19. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol.* 1998;16(2):405-410.
20. Luigi Rossi, Monica Verrico, Eleonora Zaccarelli, et al. Bevacizumab in ovarian cancer: A critical review of phase III studies. *Oncotarget.* 2017 Feb 14; 8(7): 12389–12405.
21. Carboplatin/pegylated liposomal Doxorubicin/Bevacizumab (CD-BEV) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in patients with recurrent ovaria. A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO Study Group, AGO-Austra, ANZGOG, GINECO, SGCTG). ESMO Congress 2018; Munch, Germany. Abstract 9330.
22. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 2017;357:409-413.